[go: up one dir, main page]

WO2008022060A3 - Imidazo-pyridine derivatives for modulating protein kinase activity - Google Patents

Imidazo-pyridine derivatives for modulating protein kinase activity Download PDF

Info

Publication number
WO2008022060A3
WO2008022060A3 PCT/US2007/075771 US2007075771W WO2008022060A3 WO 2008022060 A3 WO2008022060 A3 WO 2008022060A3 US 2007075771 W US2007075771 W US 2007075771W WO 2008022060 A3 WO2008022060 A3 WO 2008022060A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein kinase
kinase activity
imidazo
pyridine derivatives
modulating protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/075771
Other languages
French (fr)
Other versions
WO2008022060A2 (en
Inventor
Christopher Thomas Brain
Kim Sunkyu
David L Farley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2008022060A2 publication Critical patent/WO2008022060A2/en
Publication of WO2008022060A3 publication Critical patent/WO2008022060A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application describes compounds of formula (I) that are useful for the treatment, prevention and/or amelioration of diseases, associated with protein kinase activity. Wherein : R1 is a thiophen or a phenyl substituted with C1-C6 alkoxyl, C1-C6 alkoxyl R2 is a piperidine substituted by C(O)-R3 or R4
PCT/US2007/075771 2006-08-14 2007-08-13 Imidazo-pyridine derivatives for modulating protein kinase activity Ceased WO2008022060A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82226706P 2006-08-14 2006-08-14
US60/822,267 2006-08-14

Publications (2)

Publication Number Publication Date
WO2008022060A2 WO2008022060A2 (en) 2008-02-21
WO2008022060A3 true WO2008022060A3 (en) 2008-12-31

Family

ID=39083015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075771 Ceased WO2008022060A2 (en) 2006-08-14 2007-08-13 Imidazo-pyridine derivatives for modulating protein kinase activity

Country Status (1)

Country Link
WO (1) WO2008022060A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445515B2 (en) 2008-12-22 2013-05-21 Chemocentryx, Inc. C5aR antagonists
US9126939B2 (en) 2010-06-24 2015-09-08 Pingchen Fan C5AR antagonists
US9745268B2 (en) 2014-09-29 2017-08-29 Chemocentryx, Inc. Processes and intermediates in the preparation of C5aR antagonists
US11285138B2 (en) 2016-01-14 2022-03-29 Chemocentryx, Inc. Method of treating C3 glomerulopathy

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019011116A (en) * 2017-03-22 2020-02-05 Liao Xibin Bruton's tyrosine kinase inhibitors.
CN113811533A (en) * 2019-03-15 2021-12-17 艾特里提治疗有限公司 Compounds and methods for treating disease
WO2024092222A1 (en) * 2022-10-28 2024-05-02 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor d and related products and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019828A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Kinase inhibitors as therapeutic agents
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
WO2004058264A1 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor
WO2005021545A1 (en) * 2003-09-03 2005-03-10 Galapagos Nv IMIDAZO[1,5-a]PYRIDINE OR IMIDAZO[1,5-a]PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019828A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Kinase inhibitors as therapeutic agents
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
WO2004058264A1 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor
WO2005021545A1 (en) * 2003-09-03 2005-03-10 Galapagos Nv IMIDAZO[1,5-a]PYRIDINE OR IMIDAZO[1,5-a]PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445515B2 (en) 2008-12-22 2013-05-21 Chemocentryx, Inc. C5aR antagonists
US8906938B2 (en) 2008-12-22 2014-12-09 Chemocentryx, Inc. C5aR antagonists
US10660897B2 (en) 2008-12-22 2020-05-26 Chemocentryx, Inc. C5aR antagonists
US9126939B2 (en) 2010-06-24 2015-09-08 Pingchen Fan C5AR antagonists
US9573897B2 (en) 2010-06-24 2017-02-21 Chemocentryx, Inc. C5AR antagonists
US10035768B2 (en) 2010-06-24 2018-07-31 Chemocentryx, Inc. C5aR antagonists
US9745268B2 (en) 2014-09-29 2017-08-29 Chemocentryx, Inc. Processes and intermediates in the preparation of C5aR antagonists
US10266492B2 (en) 2014-09-29 2019-04-23 Chemocentryx, Inc. Processes and intermediates in the preparation of C5aR antagonists
US10532982B2 (en) 2014-09-29 2020-01-14 Chemocentryx, Inc. Processes and intermediates in the preparation of C5aR antagonists
US11845729B2 (en) 2014-09-29 2023-12-19 Chemocentryx, Inc. Processes and intermediates in the preparation of C5aR antagonists
US11285138B2 (en) 2016-01-14 2022-03-29 Chemocentryx, Inc. Method of treating C3 glomerulopathy

Also Published As

Publication number Publication date
WO2008022060A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2008022060A3 (en) Imidazo-pyridine derivatives for modulating protein kinase activity
WO2006023515A3 (en) Novel thiazole inhibitors of fructose 1,6-bisphosphatase
WO2007140385A3 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
WO2007143422A3 (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2007136592A3 (en) 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
WO2004035569A3 (en) Novel compounds with antibacterial activity
WO2008080015A3 (en) Compounds and methods for kinase modulation, and indications therefor
WO2008122375A3 (en) Insecticidal aryl isoxazoline derivatives
WO2008057775A3 (en) Heterocyclic amide compounds useful as kinase inhibitors
WO2006094292A3 (en) Thienopyridine compounds, and methods of use thereof
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
MY153971A (en) Sulfonamides as trpm8 modulators
WO2008011130A3 (en) Amide compounds
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
WO2009051244A1 (en) Heterocyclic compound
DK2123271T3 (en) Medication for the treatment of influenza
WO2005074642A3 (en) Chemical compounds
WO2005097788A3 (en) Sulfonamides and uses thereof
WO2008128639A8 (en) Thiadiazolyl oxyphenyl amidines and the use thereof as a fungicide
WO2007056159A3 (en) Hydrazone derivatives and uses thereof
NO20082096L (en) Azaindole-2-karboksamidderivativer
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
NO20080394L (en) N- (arylalkyl) -1H-pyrrolopyridine-2-carboxamide derivatives, preparation and use thereof
WO2008030795A3 (en) Compositions and methods for inhibition of tyrosine kinases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07814015

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07814015

Country of ref document: EP

Kind code of ref document: A2